📅 PUBMED DAILY TRIAGE — 2026-04-23
Window: 2026-04-22T09:00:00Z → 2026-04-23T09:00:00Z (CRDT) Topics scanned: 9 | Articles reviewed: ~51 candidates across all topics | Kept: 25 High priority: 6 | Standard: 16 | Low/archive: 3 | Unsolicited finds: 0 Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Early Cancer Detection (Liquid Biopsy / ctDNA / cfDNA)
TR-2026-04-23-001 / PMID 42020781 · A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas · 9/10 · Leukemia; n=123 uniformly treated LBCL; targeted ctDNA duplex sequencing outperforms FISH for TP53 loss risk stratification — directly actionable for liquid biopsy adoption in aggressive lymphoma management.
TR-2026-04-23-002 / PMID 42014847 · Enhanced multicancer screening assay through whole-genome methylation sequencing-based multimodal cfDNA analysis · 9/10 · Exp Mol Med; n=1415; 8 cancer types; 93.2% sensitivity / 95% specificity / 92.3% stage I sensitivity — one of the strongest multicancer early detection results reported to date. ⚠️ Note: Corresponding author is founder of IMBdx Inc.; independent replication warranted. Deferred from 2026-04-22 run — abstract successfully resolved.
Novel Therapeutics
TR-2026-04-23-003 / PMID 42019833 · YAP1 defines an emergent, plastic population of relapsed small cell lung cancer · 8/10 · J Thorac Oncol; MD Anderson; ctDNA/CTC/biopsy analysis of chemo-resistant SCLC identifies YAP1+ persister cells with novel targetable antigens (B7-H3, TROP2) — directly frames ADC trial targets in resistant SCLC.
TR-2026-04-23-005 / PMID 42020851 · First-Line Therapy for Advanced RCC: IO-TKI vs IO-IO in the TOURS Multicenter Study · 8/10 · Target Oncol; n=324 propensity-matched; IO-TKI shows significantly better PFS (17.1 vs 8.4 mo) and OS (51.7 vs 31.5 mo) over dual IO in IMDC int/poor-risk — real-world comparative evidence for first-line treatment selection in aRCC.
Precision Oncology / Genomic Medicine
TR-2026-04-23-004 / PMID 42020736 · Quadruple pegRNA enables programmable and efficient large genomic insertion · 8/10 · Nature; QuadPE achieves ~40% integration efficiency for DNA fragments up to 26 kb in human primary T cells and neurons — breaks the large-insert efficiency barrier in prime editing with direct implications for CAR-T engineering and rare monogenic disease correction.
Rare Diseases
TR-2026-04-23-006 / PMID 42020622 · Electrochemotherapy in pediatrics: a systematic review · 8/10 · Eur Radiol; 127 pediatric patients; 97-100% complete tumor response; 52-100% vascular anomaly volume reduction — first pediatric ECT systematic review; high response rates support wider adoption for pediatric tumors/VAs with limited alternatives.
🟢⚪ STANDARD (5-7) — Top by Topic
Hematologic Malignancies
- TR-2026-04-23-007 / PMID 42020921 · Venetoclax capillary microsampling validation, AML/CLL, n=25 · 6/10 · Diagnostics
- TR-2026-04-23-021 / PMID 42020817 · Nurse-led remote symptom management lymphoma, n=429, significant toxicity reduction · 5/10 · Treatment Innovation
Early Cancer Detection
- TR-2026-04-23-009 / PMID 42020129 · Nurse-led SDM for lung cancer LDCT, meta-analysis n=13,608, non-inferior uptake vs standard care · 7/10 · Early Detection
- TR-2026-04-23-008 / PMID 42020802 · Long COVID endovascular pediatrics, microclots + cfDNA/NETosis, n=84 · 7/10 · Diagnostics
AI/ML in Clinical Diagnostics
- TR-2026-04-23-012 / PMID 42020919 · COVID elderly ML antiviral response (Geroscience), multicenter Spanish cohort · 7/10 · Diagnostics
- TR-2026-04-23-012 / PMID 42020520 · Explainable AI + proteomics for hypertension biomarkers, Qatar Biobank n=778, AUROC 0.80 · 7/10 · Diagnostics
- TR-2026-04-23-016 / PMID 42020503 · LLM causal reasoning for lab test interpretation, GPT-o1 vs Llama, AUROC 0.80 · 6/10 · Diagnostics
- TR-2026-04-23-019 / PMID 42020789 · CTA ML prediction of carotid IPH, random forest AUC 0.679 · 5/10 · Diagnostics
Precision Oncology / Genomic Medicine
- TR-2026-04-23-017 / PMID 42020210 · CDK inhibitor landscape review (Trends Cancer, MD Anderson/IEO) · 6/10 · Drug Development
- TR-2026-04-23-013 / PMID 42020658 · Multi-ancestry GWAS melatonin aMT6s, n=11,744, no GWS hits but PRS-T2D association · 7/10 · Genomics/Precision Medicine
Novel Therapeutics
- TR-2026-04-23-014 / PMID 42020818 · γδ T cells in colorectal/liver cancer (Nat Rev Gastroenterol Hepatol) · 6/10 · Treatment Innovation
- TR-2026-04-23-020 / PMID 42020832 · Sphingomyelinase inhibitors enhance NK cell lung cancer killing (preclinical) · 5/10 · Drug Development
- TR-2026-04-23-024 / PMID 42020933 · FUAS + ICI in NSCLC liver mets, n=10, DCR 80% at 12 weeks · 6/10 · Treatment Innovation
Cardiovascular-Metabolic
- TR-2026-04-23-015 / PMID 42020826 · Visfatin/TLR4 vascular calcification suppressed by empagliflozin · 6/10 · Drug Development
- TR-2026-04-23-018 / PMID 42020705 · T2D dietary patterns across validated subtypes, SMART2D n=1007 · 6/10 · Prevention
- TR-2026-04-23-022 / PMID 42020141 · SES + intracranial plaque, cardiometabolic mediation, n=3065 · 6/10 · Public Health
Aging / Longevity
- TR-2026-04-23-011 / PMID 42020929 · MMP-10 + osteopontin AD biomarkers (UCL/Zetterberg group), n=137 · 7/10 · Diagnostics
- TR-2026-04-23-025 / PMID 42020920 · ChREBP DNL regulation in 5 long-lived mouse models · 5/10 · Other
Rare Diseases
- TR-2026-04-23-023 / PMID 42020528 · NF1 pregnancy psychosocial experiences, qualitative n=14 · 5/10 · Mental Health
💡 UNSOLICITED FINDS
None. All sentinel scan results matched active watchlist topics. Sentinel search: 1,149 raw results; top 5 reviewed; 0 unsolicited articles identified.
📊 TODAY'S BREAKDOWN
By research category:
- Diagnostics: 8 | Treatment Innovation: 6 | Drug Development: 3 | Early Detection: 2 | Genomics/Precision Medicine: 2 | Prevention: 2 | Public Health: 2 | Mental Health: 1 | Other: 1
By evidence maturity:
- Exploratory: 17 | Validated: 7 | Potentially Practice-Changing: 0
By watchlist topic (reviewed / kept / highest score):
| Topic | Reviewed | Kept | Highest |
|---|---|---|---|
| Hematologic malignancies | 6 | 5 | 9 (PMID 42020781) |
| Early cancer detection | 7 | 6 | 9 (PMID 42014847) |
| CBC/ML hematology | 4 | 4 | 7 (PMID 42020919) |
| AI/ML diagnostics & imaging | 5 | 4 | 7 (PMID 42020520) |
| Precision oncology / genomics | 5 | 4 | 8 (PMID 42020736) |
| Novel therapeutics | 5 | 5 | 8 (PMID 42019833, 42020851) |
| Cardiovascular-metabolic | 5 | 4 | 6 |
| Aging / longevity | 5 | 4 | 7 (PMID 42020929) |
| Rare diseases | 4 | 3 | 8 (PMID 42020622) |
By source type: peer_reviewed: 25 | preprint: 0
Topics with zero 8+ articles: CBC/ML hematology, AI/ML diagnostics, Cardiovascular-metabolic, Aging/longevity
🔧 RUN NOTES
- Window expansion: Not triggered (≥5 relevant articles found in standard 24h window).
- Deferred PMID resolved: PMID 42014847 (deferred from 2026-04-22 due to abstract parse failure) successfully retrieved and scored HIGH (9/10); included in this run.
- Sentinel scan: 1,149 raw results from broad signal query; top 5 IDs reviewed; all matched existing watchlist topics; 0 unsolicited finds.
- AI/ML diagnostics topic: 192 raw results; cap applied at 10 candidates; top 5 reviewed after cross-topic deduplication; 0 articles scored 8+.
- Cardio-metabolic GLP-1/SGLT2 note: 153 raw results; strongest find (PMID 42020826) is preclinical mechanism study for empagliflozin/visfatin — no RCT-level cardio-metabolic finds today.
- Rolling 7-day note: CBC/ML hematology and AI/ML diagnostics have now produced 0 HIGH articles for 3 consecutive days; Cardiovascular-metabolic has produced 0 HIGH for 2 consecutive days (based on state notes).
- Data quality: All articles abstract-only; no PMC full text retrieved. Classification confidence: high for 22/25 articles, medium for 3/25.